Psyence Biomedical
Psyence Biomedical is a pre-revenue, Toronto-based clinical-stage biopharmaceutical company developing nature-derived psilocybin (NPX-5) and ibogaine therapeutics for palliative care mental health, substance use disorders, and longevity, with GMP manufacturing through its PsyLabs subsidiary in Southern Africa.
- Company typePublic
- Founded2023
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Psyence Biomedical does
Psyence Biomedical Ltd. (NASDAQ: PBM) is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada, developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic therapeutics for mental health disorders. Its lead asset NPX-5, a GMP-compliant, nature-derived psilocybin candidate formulated as 25mg capsules, is currently being evaluated in a Phase IIb clinical trial across five Australian sites for the treatment of Adjustment Disorder in cancer patients in palliative care. The trial enrolls approximately 87 participants and combines psilocybin administration with structured psychotherapy.
The company's technology platform is anchored by its investment in PsyLabs (Psyence Labs Ltd.), a GMP-compliant, ISO 22000-certified manufacturing operation in Southern Africa that handles the full supply chain from cultivation at source, through extraction and purification, to pharmaceutical-grade API production. PsyLabs supplies both psilocybin (used in the NPX-5 program) and pharmaceutical-grade ibogaine HCl and total alkaloid extracts for substance use disorder indications. Following a February 2026 share-for-share exchange, PsyLabs holds approximately 49.98% of Psyence BioMed's outstanding shares, effectively consolidating the upstream manufacturer and clinical developer under shared ownership.
Psyence is pre-revenue, with no registered commercial products and no disclosed pricing. Its cash position stood at approximately $9-12 million as of late 2025 / early 2026, with no debt. The company monetizes through future regulatory approval and commercialization of its psychedelic therapeutic candidates, targeting three primary use cases: palliative care mental health (Adjustment Disorder in cancer patients), substance use disorders (opioid and alcohol addiction via ibogaine), and a newly launched longevity research program investigating psilocybin's effects on biological aging markers. Go-to-market relies on clinical trial partnerships with Australian research institutions and CROs, conference-driven investor engagement (H.C. Wainwright, ICPR 2026), and emerging U.S. policy engagement around ibogaine research.
Psyence Biomedical firmographics
Firmographics- Name
- Psyence Biomedical
- Legal name
- Psyence Biomedical Ltd.
- Website
- https://psyencebiomed.com
- Company type
- Public
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Psyence Biomedical is a pre-revenue, Toronto-based clinical-stage biopharmaceutical company developing nature-derived psilocybin (NPX-5) and ibogaine therapeutics for palliative care mental health, substance use disorders, and longevity, with GMP manufacturing through its PsyLabs subsidiary in Southern Africa.
- Ownership category
- akta.pro rank
Psyence Biomedical industry classification
Industry- Product category
- Psychedelic Therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Psyence Biomedical is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Psyence Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical stage company with no registered commercial products. Future revenue expected from FDA-approved nature-derived psychedelic treatments for mental health disorders following successful clinical development and regulatory approval.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Psyence Biomedical product offering
Product offeringCore offering
Psyence Biomedical is a clinical-stage biopharmaceutical company developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicines for mental health disorders in palliative care, addiction, and longevity applications. The company conducts Phase IIb clinical trials with its lead candidate NPX-5 (psilocybin) for Adjustment Disorder in cancer patients, and develops pharmaceutical-grade ibogaine for substance use disorders. Manufacturing is secured through strategic investment in PsyLabs, a GMP-compliant psychedelic API production facility in Southern Africa.
Product overview
Psyence Biomedical operates as a vertically integrated biopharmaceutical company developing nature-derived psychedelic therapeutics. The company focuses on two core products: NPX-5, a GMP-compliant nature-derived psilocybin candidate in Phase IIb trials for Adjustment Disorder in cancer patients, and pharmaceutical-grade ibogaine for substance use disorders. Manufacturing capabilities are secured through strategic investment in PsyLabs, which operates a GMP-compliant facility in Southern Africa producing psychedelic APIs including psilocybin and ibogaine. The company combines drug development with psychotherapy protocols, operating clinical trials across multiple Australian sites.
Differentiator
Problem solved
Functional benefit
Brands
- NPX-5: GMP-compliant, nature-derived psilocybin candidate (25mg dose) for treatment of Adjustment Disorder in cancer patients in palliative care
- PsyLabs
- Psyence Labs
Products and services
- NPX-5 (Nature-Derived Psilocybin) A GMP-compliant, nature-derived (non-synthetic) psilocybin candidate formulated as 25mg capsules for use in Phase IIb clinical trials evaluating treatment of Adjustment Disorder in cancer patients in palliative care.
- Pharmaceutical-Grade Ibogaine GMP-compliant, pharmaceutical-grade ibogaine (including ibogaine HCl and total alkaloid extracts) produced through vertical integration with PsyLabs at source in Africa, supporting clinical development for substance use disorders and research initiatives.
- Psilocybin-Assisted Psychotherapy Therapeutic treatment approach combining nature-derived psilocybin (NPX-5) with structured psychotherapy for treatment of Adjustment Disorder in palliative care patients with cancer.
Quantifiable outcome
- Phase IIb trial for Adjustment Disorder in palliative care - 87 participants across 5 Australian sites, top-line results expected 2026
- +2 more outcomes
Companies that use Psyence Biomedical
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Psyence Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Psyence Biomedical partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- PsyLabscoreStrategic manufacturing partnership through multi-stage investment ($500,000 in April 2025, $3.5 million in November 2025, $5 million share-for-share exchange in February 2026). PsyLabs operates GMP-compliant manufacturing facility in Southern Africa producing pharmaceutical-grade psilocybin and ibogaine. PsyLabs owns 49.98% equity stake in Psyence BioMed. PsyLabs is federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including ibogaine, operating from ISO 22000 and GMP-compliant facility.
- Southern Star ResearchcoreAward-winning, full-service Australian Contract Research Organization (CRO) providing clinical trial management services for Phase IIb study. Partnership accelerates development of psilocybin-assisted therapy for Adjustment Disorder through operational expertise and regulatory compliance support.
- Empax CentreminorClinical trial site in Perth, Australia conducting Phase IIb dosing of natural psilocybin for Adjustment Disorder in palliative care patients.
- Mind Medicine Australia ClinicminorClinical trial site in Melbourne, Australia conducting Phase IIb dosing as part of expanding clinical site network.
- Paratus Clinical ResearchminorClinical trial site in Melbourne, Australia activated to expand Phase IIb study to three actively enrolling sites and accelerate data collection.
- Ramsay Health CareminorAdded to Australian clinical site network expanding from three to five sites to support Phase IIb trial. Ramsay Health Care is a major healthcare provider with multiple facilities.
- NeuroCentrixminorAdded to Australian clinical site network to support Phase IIb trial expansion and accelerate patient recruitment.
- Australian Clinical Trial NetworkminorPartnership for Phase IIb trials mentioned in site management organization market report as notable strategic alliance in psychedelic therapeutics sector.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Psyence Biomedical competitors and assessment
Company assessmentDirect peers
- Compass Pathways: Lead clinical-stage competitor developing synthetic psilocybin (COMP360) for treatment-resistant depression; the most directly comparable public psychedelic biopharma pursuing CNS indications with rigorous Phase II/III trials.
- MindMed: Clinical-stage psychedelic medicine company developing LSD-based therapies and psilocybin for anxiety and ADHD; comparable as a public psychedelic therapeutics peer targeting CNS/mental health indications.
- Atai Life Sciences: Clinical-stage biopharma developing psychedelic and non-psychedelic compounds for mental health (depression, anxiety, addiction); directly comparable as a multi-asset psychedelic platform with similar go-to-market approach.
- GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) for treatment-resistant depression; a directly comparable psychedelic therapeutics peer with a similar late-stage clinical focus.
- Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analogs (CYB003) for depression and anxiety; competes in the same psilocybin-based CNS indication space.
- Filament Health: Developer of natural psilocybin drug candidates with proprietary extraction and manufacturing; the closest peer to Psyence's nature-derived (non-synthetic) psilocybin positioning.
- Small Pharma (now atai): Formerly Small Pharma (acquired by atai in 2024), developed deuterated DMT (SPL026) for depression; directly comparable as a clinical-stage DMT-based psychedelic therapeutics company.
Emerging players
- Beckley Psytech: Private clinical-stage company developing synthetic psilocybin (BPL-003) for treatment-resistant depression and other CNS indications; an emerging peer with overlapping psychedelic CNS pipeline.
- Delix Therapeutics: Clinical-stage company developing novel neuroplastogens (non-hallucinogenic psychoplastogens) for CNS indications; an emerging peer pursuing psychedelic-inspired CNS therapies.
Broad incumbents
- MAPS / Lykos Therapeutics: Established psychedelic therapeutics organization advancing MDMA-assisted therapy (now via Lykos Therapeutics); broader incumbent in psychedelic medicine with a commercial-stage focus in PTSD that informs the regulatory environment Psyence operates in.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Psyence Biomedical social profiles
Digital presencePsyence Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Psyence Biomedical leadership team
Management profileNumber of profiles
Profiles4 records
Psyence Biomedical subsidiaries and ownership
Company hierarchySubsidiaries2 records
Psyence Biomedical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Psyence Biomedical M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Psyence Biomedical
What does Psyence Biomedical do?
Psyence Biomedical is a clinical-stage biopharmaceutical company developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicines for mental health disorders in palliative care, addiction, and longevity applications. The company conducts Phase IIb clinical trials with its lead candidate NPX-5 (psilocybin) for Adjustment Disorder in cancer patients, and develops pharmaceutical-grade ibogaine for substance use disorders. Manufacturing is secured through strategic investment in PsyLabs, a GMP-compliant psychedelic API production facility in Southern Africa.
Is Psyence Biomedical a public or private company?
Psyence Biomedical is a public company. It is classified as public and is currently operating.
When was Psyence Biomedical founded?
Psyence Biomedical was founded in 2023. It employs 11 to 50 people.
Where is Psyence Biomedical based?
Psyence Biomedical is headquartered in Toronto, Canada, in the North America region.
How does Psyence Biomedical make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Psyence Biomedical's main competitors?
Direct peers on record are Compass Pathways, MindMed, Atai Life Sciences, GH Research, Cybin, Filament Health and Small Pharma (now atai). Emerging players are Beckley Psytech and Delix Therapeutics. MAPS / Lykos Therapeutics is listed as a broad incumbent.
Does Psyence Biomedical have an API?
No public API is recorded for Psyence Biomedical.
What industry is Psyence Biomedical in?
Psyence Biomedical's product category is Psychedelic Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2834.